$1.71 Million in Sales Expected for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) This Quarter

Wall Street brokerages predict that Aclaris Therapeutics, Inc. (NASDAQ:ACRS) will report $1.71 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Aclaris Therapeutics’ earnings, with the highest sales estimate coming in at $1.80 million and the lowest estimate coming in at $1.58 million. Aclaris Therapeutics reported sales of $2.05 million during the same quarter last year, which indicates a negative year-over-year growth rate of 16.6%. The company is scheduled to report its next earnings results on Friday, August 6th.

On average, analysts expect that Aclaris Therapeutics will report full-year sales of $6.92 million for the current fiscal year, with estimates ranging from $6.50 million to $7.40 million. For the next financial year, analysts expect that the company will report sales of $7.18 million, with estimates ranging from $6.41 million to $8.10 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Aclaris Therapeutics.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Thursday, May 6th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.27). Aclaris Therapeutics had a negative return on equity of 107.60% and a negative net margin of 936.71%. The business had revenue of $1.78 million for the quarter, compared to the consensus estimate of $1.47 million.

A number of research analysts have recently commented on the company. Zacks Investment Research upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 13th. HC Wainwright assumed coverage on Aclaris Therapeutics in a research note on Wednesday, April 21st. They issued a “buy” rating for the company. Finally, Piper Sandler assumed coverage on Aclaris Therapeutics in a research note on Tuesday, June 15th. They issued an “overweight” rating for the company.

NASDAQ ACRS traded down $0.02 on Friday, hitting $15.74. 4,356 shares of the company’s stock were exchanged, compared to its average volume of 903,643. Aclaris Therapeutics has a 52 week low of $1.82 and a 52 week high of $30.38. The company has a debt-to-equity ratio of 0.10, a current ratio of 9.27 and a quick ratio of 9.27. The business has a 50-day moving average price of $18.95.

In other Aclaris Therapeutics news, insider David N. Gordon sold 2,631 shares of the stock in a transaction dated Tuesday, July 13th. The stock was sold at an average price of $16.98, for a total transaction of $44,674.38. Following the completion of the sale, the insider now directly owns 147,447 shares in the company, valued at approximately $2,503,650.06. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Frank Ruffo sold 27,339 shares of the firm’s stock in a transaction dated Monday, April 26th. The shares were sold at an average price of $25.80, for a total value of $705,346.20. Following the completion of the sale, the chief financial officer now owns 209,059 shares of the company’s stock, valued at $5,393,722.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 122,138 shares of company stock valued at $2,856,286. 8.20% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of ACRS. Royal Bank of Canada grew its stake in Aclaris Therapeutics by 85.6% in the 1st quarter. Royal Bank of Canada now owns 3,515 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 1,621 shares in the last quarter. Dorsey Wright & Associates grew its position in Aclaris Therapeutics by 135.0% in the first quarter. Dorsey Wright & Associates now owns 6,110 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 3,510 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Aclaris Therapeutics by 6.2% in the first quarter. Bank of New York Mellon Corp now owns 111,156 shares of the biotechnology company’s stock worth $2,801,000 after purchasing an additional 6,537 shares during the last quarter. HighTower Advisors LLC lifted its stake in Aclaris Therapeutics by 12.1% in the first quarter. HighTower Advisors LLC now owns 64,478 shares of the biotechnology company’s stock worth $1,624,000 after purchasing an additional 6,978 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new stake in Aclaris Therapeutics in the first quarter worth $204,000. 87.15% of the stock is currently owned by institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation.

Featured Article: What is the formula for calculating total return?

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.